ImmERge Labs cofounder Marion Leary was walking home from the Philadelphia Eagles parade last Thursday, amid a city overcome with joy when, suddenly, she bumped into the very problem her startup is trying to fix.
Surrounded by police officers and a small crowd, a middle-age overdose victim lay motionless on a North Philly sidewalk.
A woman was atop the victim, delivering compressions to the center of their chest. Despite her poor technique, the good Samaritan was trying to bring the victim back to life, as first responders waited for the Narcan to kick in.
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous pregnancy with better outcomes after a melanoma diagnosis. Now, a research team from Perelman School of Medicine at the University of Pennsylvania says it may have determined the reason for the melanoma-protective effect. The mechanism is related to a cellular protein called the G protein-coupled estrogen receptor (GPER). When GPER was activated and combined with anti PD-1inhibitor drugs in mouse cancer models, the therapy dramatically extended survival in all animals and completely eliminated the tumor in 50 percent of the mice. Researchers published their findings in the journal eLife today.
It’s been quite a year for scientist Marion Leary.
First, her startup ImmERge Labs spun out from Penn, kicking things off by landing the $50,000 first prize at the AppItUP Demo Day. Then, she scores Geek of the Year at the Philly Geek Awards. And now, her company was announced as one of seven tech startups joining the University City Science Center’s Digital Health Accelerator.
The woman on the treadmill next to you at the gym collapses. You rush to her side, but she’s not breathing and has no pulse. Do you know what to do next?
If not, virtual reality may be the key to saving her life.
Unlike a heart attack, which occurs when blood flow to the heart is blocked, sudden cardiac arrest (SCA) is triggered by electrical malfunction. It comes on suddenly and often without warning.
The heart stops beating. Blood can’t reach the brain, lungs, and other vital organs. The victim loses consciousness and, without treatment, will die within minutes.
American Crane recently had the opportunity to open their facility to the ImmERge Labs, an Upstart company spun out of the University of Pennsylvania, to introduce their employees to some of the newest and most innovative technology being applied in the medical field today.
After recently completing their official CPR certification training, American Crane’s employees had the chance to experience what would happen in a real life situation where they had to perform CPR through ImmERge Labs’ new CPR Virtual Teachable Moment℠ program.
Virtual reality has been a staple of science fiction ever since Stanley G. Weinbaum wrote about high-tech goggles in 1935’s Pygmalion’s Spectacles. Now that virtual reality has become actual reality, it’s slowly but surely revolutionizing the treatment of heart disease and stroke.
What Debra Travers really wanted to be was a marine biologist, until “I found out Jacques Cousteau wasn’t hiring.”
How she wound up as chief executive of PolyAurum LLC, a Philadelphia start-up developing biodegradable gold nanoparticles for treating cancerous tumors, involved a professional journey of more than 30 years in pharmaceutical and diagnostics industries, and a personal battle with the disease she’s now in business to defeat.
CARMA Therapeutics Inc., a biotechnology company developing cellular immunotherapies, co-founded by the University of Pennsylvania (Penn), announced today that it has closed an initial financing. The financing was co-led by AbbVie Ventures and HealthCap with participation by Grazia Equity and IP Group Inc. CARMA Therapeutics is building a pipeline of cancer programs using its proprietary CARMA platform, combining chimeric antigen receptor targeting with macrophages to tackle solid tumors. The proceeds will be used primarily to advance the development of its first product, CARMA-0508, an adoptive cellular immunotherapy using chimeric antigen receptor macrophages (CARMA) for the treatment of metastatic solid tumors. Specific terms of the financing transaction were not disclosed.
Earlier this month, the University of Pennsylvania’s Saar Gill turned up at ASCO to present new data demonstrating that a combination of Imbruvica with Novartis’ next-gen CAR-T CTL119 proved very effective in treating particularly lethal cases of chronic lymphocytic leukemia, wiping out all signs of the disease in 8 of 9 treatment-resistant patients enrolled in an exploratory study.
Last time we saw Ghost Robotics’ Minitaur (which was also the first time we saw Ghost Robotics’ Minitaur), it was getting around mostly by using a sort of hopping or bounding gait. Minitaur can move fairly quickly like this, but one of the advantages that it has as a quadruped is the potential to use a variety of different gaits to help it adapt to different conditions.
In a new video just posted today, Minitaur demonstrates how it’s able to handle all kinds of terrain by dynamically adjusting its gait. And it can climb. And jump. And walk on ice. And walk on two legs. And lots of other things!